(Reuters) - Mylan NV (O:MYL) reported a 7.4% rise in third-quarter profit on Tuesday, as the generic drugmaker benefited from new product launches.
The company, which in July said it would merge with Pfizer Inc's (N:PFE) off-patent branded drugs unit, said net earnings rose to $189.8 million, or 37 cents per share, in the quarter ended Sept 30 from $176.7 million, or 34 cents per share, a year earlier.
Total revenue rose to $2.96 billion from $2.86 billion.